{"id":"NCT01012258","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects","officialTitle":"Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2010-09","completion":"2014-05","firstPosted":"2009-11-13","resultsPosted":"2012-08-14","lastUpdate":"2015-07-09"},"enrollment":70,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Squamous Cell Carcinoma of the Head and Neck"],"interventions":[{"type":"BIOLOGICAL","name":"Cetuximab + concomitant boost radiotherapy","otherNames":["ErbituxÂ®"]}],"arms":[{"label":"Cetuximab","type":"EXPERIMENTAL"}],"summary":"Primary objective: to assess the antitumor activity and safety profile of cetuximab when given in combination with radiotherapy (RT) for the treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN) in Chinese subjects.\n\nSecondary objective: to assess the pharmacokinetic (PK) profile and immunogenicity of cetuximab in Chinese subjects.\n\nFurther objective: to identify for cetuximab potential predictive biomarkers of response and safety.","primaryOutcome":{"measure":"Best Overall Response (BOR)","timeFrame":"Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 3 months following the 8 weeks after the end of RT visit until the end of trial (EOT) visit","effectByArm":[{"arm":"Cetuximab","deltaMin":68.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":19},"locations":{"siteCount":8,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":66},"commonTop":["Mucosal inflammation","Weight decreased","Dermatitis acneiform","Dry mouth","Pyrexia"]}}